Connie S Phillips

US Patent:

20200407426, Dec 31, 2020

Filed:

Dec 7, 2016

Appl. No.:

16/060304

Inventors:

- Le Center MN, US
Bradley M. Mitteness - Ghent MN, US
Connie Phillips - Ankeny IA, US

International Classification:

C07K 16/00
C07K 16/12

Abstract:

Neutralizing antibodies through recombinant protein expression were identified by mining antibody repertoires by high-throughput second generation sequencing. Sequencing across the majority of light and heavy chain variable regions of chicken immunoglobulins was performed at two immunological time points: a non-immune (naive) state and a post-hyperimmunization state. The mRNA was extracted from unsorted and unselected PBMC populations and identification of antigen-specific antibody sequences leveraged the significant disparity of abundance of an individual B cell clone in non-immune and immunized states. Through bioinformatic analysis, candidate amino acid sequences for variable heavy chain and light chains were identified. Recombinant polypeptides with the binding domains having the identified amino acid sequences for variable heavy chain and light chains were expressed and screened using immunoassays to confirm antigen-specificity.

US Patent:

20140271501, Sep 18, 2014

Filed:

Mar 14, 2014

Appl. No.:

14/211947

Inventors:

- Le Center MN, US
Connie Phillips - St. Peter MN, US

Assignee:

Camas Incorporated - Le Center MN

International Classification:

A61K 39/395
A61K 9/00
A61K 39/40

US Classification:

424 54, 4241301, 4241651, 4241641, 4241591, 4241721

Abstract:

The present disclosure relates to methods and compositions administered to the lymphatic tissue of an animal to prevent or reduce the incidence of disease or disease symptoms caused by one or more disease causing entities. Tonsillar compositions can be administered to the lymphatic tissue in the oral/nasal region of the animal and can include avian antibodies from eggs of hens inoculated with one or more target disease causing entities. Treating the lymphatic tissue in the oral/nasal region with the compositions described herein can reduce or prevent the disease causing entities from adhering to the lymphatic tissue resulting in reduced infection rates. The present disclosure also relates to oral compositions that can be used to reduce or eliminate oral pathogens in animals.

US Patent:

20140017258, Jan 16, 2014

Filed:

Jul 11, 2012

Appl. No.:

13/574326

Inventors:

Bradley M Mitteness - Ghent MN, US
Connie Phillips - St. Peter MN, US

Assignee:

Camas Incorporated - Le Center MN

International Classification:

A61K 39/40
A61P 3/00
A61P 1/00
A61P 3/10
A61P 3/04
A61P 1/16
C07K 16/12
A61P 9/10

US Classification:

4241651, 5303895, 4241641, 4241691, 4241671

Abstract:

Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.

US Patent:

20130183286, Jul 18, 2013

Filed:

Mar 5, 2013

Appl. No.:

13/785838

Inventors:

Camas, Inc. - Le Center MN, US
Connie Phillips - St. Peter MN, US

Assignee:

Camas, Inc. - Le Center MN

International Classification:

A61K 39/395

US Classification:

4241301, 5303871

Abstract:

A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans.

US Patent:

20110274701, Nov 10, 2011

Filed:

May 9, 2011

Appl. No.:

13/103559

Inventors:

Bradley M. Mitteness - Ghent MN, US
Connie Phillips - St. Peter MN, US

Assignee:

Camas Incorporated - Le Center MN

International Classification:

A61K 39/395
A61K 39/44
A61P 31/12
A61P 11/00
A61P 31/16

US Classification:

4241571

Abstract:

A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans.